Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pCAR-19B in Relapsed/Refractory B-ALL
NCT04888442Phase 1Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of puzolcabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after pCAR-19B infusion at 28 days and Maximum Tolerated Dose of pCAR-19B cells at 28 days. Status: unknown.
02
Drugs
puzolcabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04888442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888442.